Rapid Reactions / SOHO 10/20/2026

How to Select Patients With CML for Ponatinib Therapy

Key Points

  • The OPTIC trial showed that a response-based dosing strategy for ponatinib improved safety with favorable efficacy for patients with chronic-phase chronic myeloid leukemia (CML).
  • Risk in CML is a continuum, and oncologists should consider all of a patient’s comorbidities and disease features to determine if ponatinib is an appropriate tyrosine kinase inhibitor (TKI).

Selecting Patients With CML for Ponatinib

Fadi Haddad, MD, of The University of Texas MD Anderson Cancer Center, and Michael W. Deininger, MD, of University of Michigan Health, discussed how long-term data from the phase 2 OPTIC trial help guide patient selection for ponatinib therapy. 

The phase 2 OPTIC trial showed that response-based doses for ponatinib reduced cardiovascular risk. The 5-year event-free survival analysis presented at the Fourteenth Annual Meeting of the Society of Hematologic Oncology supported that the 45 mg starting dose of ponatinib offers the greatest efficacy, especially for patients with T315I mutations. When using ponatinib, oncologists should follow the OPTIC dosing strategy and also optimize other factors including hypertension, hyperlipidemia, diabetes, and weight if a patient is receiving ponatinib for a long time, Dr. Haddad said. 

While CML guidelines denote specific thresholds for risk stratification, in reality risk is a continuum and picking one TKI over another in CML always requires good clinical judgment and individualized decision-making, Dr. Deininger said. The OPTIC trial enrolled patients with chronic-phase CML, but patients in this category could still have aggressive disease that may benefit from the more potent efficacy of ponatinib. Conversely, if a patient showed slow loss of molecular response, but was lower-risk or with some cardiovascular comorbidities, Dr. Deininger said he would favor asciminib or another second-generation TKI and save ponatinib for a later line of therapy. 

Overall, even with detailed guidelines, oncologists need to take an individualized look at each patient and consider if the OPTIC data supports the risks versus benefits of ponatinib, Dr. Deininger said. In addition to comorbidities, oncologists should consider disease status, treatment resistance, and mutations when developing a treatment strategy, Dr. Haddad said.